Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
Kawamura M, Shirota H, Niihori T, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Kikuchi A, Tada H, Shimada M, Kawamorita N, Kanamori M, Sugiyama I, Tsubata M, Ichikawa H, Yasuda J, Furukawa T, Aoki Y, Ishioka C. Kawamura M, et al. Among authors: shirota h. J Hum Genet. 2023 Jun;68(6):399-408. doi: 10.1038/s10038-023-01133-5. Epub 2023 Feb 20. J Hum Genet. 2023. PMID: 36804482
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens.
Saijo K, Imai H, Ouchi K, Sasaki K, Yoshida Y, Kawamura Y, Taniguchi S, Kasahara Y, Komine K, Shirota H, Takahashi M, Ishioka C. Saijo K, et al. Among authors: shirota h. Front Oncol. 2023 Aug 16;13:1230731. doi: 10.3389/fonc.2023.1230731. eCollection 2023. Front Oncol. 2023. PMID: 37664016 Free PMC article.
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Taniguchi SH, Komine K, Takenaga N, Yoshida Y, Sasaki K, Kawamura Y, Kasahara Y, Ouchi K, Imai H, Saijo K, Shirota H, Takahashi M, Ishioka C. Taniguchi SH, et al. Among authors: shirota h. Anticancer Res. 2023 Dec;43(12):5699-5704. doi: 10.21873/anticanres.16775. Anticancer Res. 2023. PMID: 38030182
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Naito Y, et al. Among authors: shirota h. JAMA Netw Open. 2022 Dec 1;5(12):e2245081. doi: 10.1001/jamanetworkopen.2022.45081. JAMA Netw Open. 2022. PMID: 36469316 Free PMC article.
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Shimoi T, et al. Among authors: shirota h. EClinicalMedicine. 2024 Feb 2;69:102447. doi: 10.1016/j.eclinm.2024.102447. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38333370 Free PMC article.
177 results